AUGMENT-101
Phase 1/2 Recruiting
447 enrolled 2 FDA
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Phase 1/2 Recruiting
15 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1/2 Recruiting
50 enrolled
MOMENTUM
Phase 1/2 Recruiting
84 enrolled
MK-3475-051
Phase 1/2 Recruiting
370 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/2 Recruiting
30 enrolled
TC011
Phase 1/2 Recruiting
98 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
439 enrolled
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Phase 1/2 Recruiting
33 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1/2 Recruiting
126 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Phase 1/2 Recruiting
24 enrolled
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/2 Recruiting
54 enrolled
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Recruiting
54 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Phase 1/2 Recruiting
940 enrolled 1 FDA
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
69 enrolled
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
48 enrolled
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Phase 1/2 Recruiting
320 enrolled
ALLight
Phase 1/2 Recruiting
83 enrolled
CAVALRY
Phase 1/2 Recruiting
104 enrolled
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 1/2 Recruiting
37 enrolled
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 Recruiting
180 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/2 Recruiting
132 enrolled
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/2 Recruiting
27 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/2 Recruiting
63 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
TranspoCART19
Phase 1/2 Recruiting
27 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Phase 1/2 Recruiting
237 enrolled
MK-3475-D20
Phase 1/2 Recruiting
176 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
MK-1045-002
Phase 1/2 Recruiting
203 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Recruiting
64 enrolled
PlaTform
Phase 1/2 Recruiting
49 enrolled
TITANium
Phase 1/2 Recruiting
174 enrolled
ACIT001/EXC002
Phase 1/2 Recruiting
63 enrolled
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
46 enrolled